Neoadjuvant Therapy Trumps Surgery in NSCLC Debate
The University of Chicago goes against Northwestern Medicine to see who will be crowned the winner in the NSCLC debate.
Dato-DXd: A Path to Potential Approval in NSCLC
Experts discussed the advancements in non–small cell lung cancer treatment and developments in both antibody-drug conjugate–based approaches and targeted therapies.
Optimizing AE Management Post CAR T-Cell Therapy in Multiple Myeloma
Experts spoke about the best practices for mitigating adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.
Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.
Exploring GPRC5D as an Important Target for Multiple Myeloma
Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.
